IntoCell
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
101 신일동로 신일동 1688-11, Daejeon, Daejeok-g...Website
www.intocell.comRevenue
<$5 MillionIndustry
ZI Rank: 1
About IntoCell
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IntoCell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if IntoCell has recently received funding, and reach out quickly before it becomes old news!
Click to see if IntoCell had a recent Job posting/layoffs
Check out if IntoCell is spiking on competitors!
Product Launch: Get notified when IntoCell launches new products
Congratulate Masked Content for being promoted to Masked Content at IntoCell
Funding: Get notified immidiatlly once IntoCell has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on IntoCell recently announced quarterly report
IntoCell, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
IntoCell Tech Stack
A closer look at the technologies used by IntoCell
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding IntoCell
IntoCell is a specialized pharmaceutical research company focused on developing innovative drug research technologies. The company aims to become a global biotechnology giant by continuously thinking outside the box. Their core technologies include OHPAS LINKER and OHPAS LINKER-TOXIN LIBRARY. IntoCell targets clients in the biotechnology and pharma... Read More
